Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Nat Med. 2022 May;28(5):946-957. doi: 10.1038/s41591-022-01786-3. | PubMed

Smita S Chandran^1,2,3, Jiaqi Ma^4,5, Martin G Klatt⁶, Friederike Dündar^7,8, Chaitanya Bandlamudi⁹, Pedram Razavi^10,11,12, Hannah Y Wen¹³, Britta Weigelt¹³, Paul Zumbo^7,8, Si Ning Fu^10,14, Lauren B Banks^10,14,11, Fei Yi^10,14, Enric Vercher¹⁰, Inaki Etxeberria¹⁰, Watchain D Bestman^11,15, Arnaud Da Cruz Paula¹⁵, Ilinca S Aricescu¹⁰, Alexander Drilon^11,12,16, Doron Betel^8,12,17, David A Scheinberg^6,11, Brian M Baker^4,5, Christopher A Klebanoff^{18,19,20,21,22,23,24}

1. Human Oncology and Pathogenesis Program (HOPP), Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandrs1@mskcc.org.
2. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandrs1@mskcc.org.
3. Parker Institute for Cancer Immunotherapy, New York, NY, USA. chandrs1@mskcc.org.
4. Department of Chemistry and Biochemistry, University of Notre Dame, South Bend, IN, USA.
5. Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
6. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7. Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
8. Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
9. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
10. Human Oncology and Pathogenesis Program (HOPP), Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
11. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
12. Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
13. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
14. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
15. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
16. Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
17. Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
18. Human Oncology and Pathogenesis Program (HOPP), Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.
19. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.
20. Parker Institute for Cancer Immunotherapy, New York, NY, USA. klebanoc@mskcc.org.
21. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.
22. Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA. klebanoc@mskcc.org.
23. Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.
24. Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. klebanoc@mskcc.org.

Presented By Smita Chandran | ORCID iD